申请人:Pfizer Inc.
公开号:US05362878A1
公开(公告)日:1994-11-08
Compounds of the formula ##STR1## wherein R.sup.21 and R.sup.22 are as defined in the specification which are intermediates useful in the preparation of compounds of the formula ##STR2## and the pharmaceutically acceptable salts thereof, wherein Q and R.sup.1 are as defined in the specification. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.
式为##STR1##的化合物,其中R.sup.21和R.sup.22如规范中所定义,这些化合物是制备式为##STR2##及其药用可接受盐的中间体,在该中间体中Q和R.sup.1如规范中所定义。式I的化合物是酰辅酶A:胆固醇酰基转移酶(ACAT)的抑制剂,可用作降脂和抗动脉粥样硬化药物。